|本期目录/Table of Contents|

[1]郭小云 综述,李荣 审校.生长分化因子-15在肾脏疾病中的研究进展[J].天津医科大学学报,2020,26(03):296-300.
点击复制

生长分化因子-15在肾脏疾病中的研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
26卷
期数:
2020年03期
页码:
296-300
栏目:
综述
出版日期:
2020-06-10

文章信息/Info

Title:
-
文章编号:
1006-8147(2020)03-0296-05
作者:
郭小云 综述;  李荣 审校
（天津医科大学第二医院肾内科，天津 300211)
Author(s):
-
关键词:
生长分化因子-15; 肾脏疾病 ; 标记物
Keywords:
-
分类号:
R692.6
DOI:
-
文献标志码:
A
摘要:
慢性肾脏疾病并发症多预后不良,是困扰我国公共卫生健康的重大问题。因此寻找用于预防和诊断肾脏疾病的生物标志物是迫在眉睫需要解决的问题。生长分化因子-15与多种疾病的进展和预后相关，近年来发现其不仅是肾脏损伤的生物标志物，在动物实验中还有肾脏保护作用。对生长分化因子-15生物学结构特点以及其在多种肾脏疾病中的作用进行综述，为早期发现、早期预防肾脏疾病提供新的思路。
Abstract:
-

参考文献/References:

[1] Lindahl B. The story of growth differentiation factor 15: another piece of the puzzle[J]. Clin Chem, 2013, 59(11):1550
[2] Wang X, Chen L L, Zhang Q. Increased serum level of growth differentiation factor 15 (GDF-15) is associated with coronary artery disease[J]. Cardiovasc Ther, 2016,34(3):138
[3] Baek S J, Eling T. Growth differentiation factor 15(GDF15):A survival protein with therapeutic potential in metabolic diseases[J].Pharmacol Ther, 2019,198(6):46
[4] Li J, Yang L J, Qin W J, et al. Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus[J]. PLoS One, 2013, 8(6):e65549
[5] Emmerson P J, Duffin K L, Chintharlapalli S A.GDF15 and growth control[J]. Front Physiol, 2018, 9(9):1712
[6] Bootcov M R, Bauskin A R, Valenzuela S M, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily[J]. Proc Natl Acad Sci U S A, 1997, 94(21):11514
[7] Ramu A, Banerjee S K. GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: a translational prospective[J]. J Diabetes Res, 2015, 2015:490842
[8] Tsai V W, Husaini Y, Sainsbury A, et al. The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases[J]. Cell Metab, 2018, 28(3):353
[9] Preusch M R, Baeuerle M, Albrecht C A, et al. GDF-15 protects from macrophage accumulation in a mousemodel of advanced atherosclerosis[J]. Eur J Med Res, 2013, 18(1):19
[10] Ding Q, Mracek T, Gonzalez-Muniesa P, et al. Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes[J]. Endocrinology, 2009, 150(4):1688
[11] Kleinert M, Clemmensen C, Sj?覬berg K A, et al. Exercise increases circulating GDF15 in humans[J]. Mol Metab, 2018, 9(3):187
[12] Hanatani S, Izumiya Y, Takashio S, et al. Growth differentiation factor-15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts[J]. Heart and vessels, 2014, 29(2):231
[13] O’Meara E, Denus S D, Rouleau J L,et al. Circulating biomarkers in patients with heart failure and preserved ejection fraction[J]. Curr Heart Fail Rep, 2013, 10(4):350
[14] Rhodes C J, Wharton J, Wilkins M R, et al. Pulmonary hypertension: biomarkers[J]. Handb Exp Pharmacol, 2013, 218:77
[15] Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P.Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus[J]. Am J Cardiol, 2014, 114(6):890
[16] Wollert K C, Kempf T, Wallentin L.Growth differentiation factor 15 as a biomarker in cardiovascular disease[J]. Clin Chem, 2017, 63(1):140
[17] Mullican S E, Rangwala S M. Uniting GDF15 and GFRAL: Therapeutic opportunities in obesity and beyond[J]. Trends Endocrinol Metab, 2018, 29(8):560
[18] Gaffney A M, Sladen R N. Acute kidney injury in cardiac surgery[J].Curr Opin Anaesthesiol, 2015, 28(1):50
[19] Sun L, Zhou X ,Jiang J, et al. Growth differentiation factor-15 levels and the risk of contrast induced nephropathy in patients with acute myocardial infarction undergoing percutaneous coronary intervention:A retrospective observation study[J]. PLoS One, 2018, 13(5):e0197609
[20] Zhang W, Chu H C, Xue F. Assessing preoperative plasma growth-differentiation factor-15 for prediction of acute kidney injury in patients undergoing cardiac surgery[J]. Crit Care, 2017, 21(1):53
[21] Guenancia C, Kahli A, Laurent G, et al. Pre-operative growth differentiation factor 15 as a novel biomarker of acute kidney injury after cardiac bypass surgery[J]. Int J Cardiol, 2015, 197:66
[22] Kahli A,Guenancia C, Zeller M A, et al. Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass[J]. PLoS One, 2014, 9(8):e105759
[23] Heringlake M, Charitos E I, Gatz N, et al. Growth differentiation factor 15:a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients[J]. J Am Coll Cardiol,2013, 61(6):672
[24] Heringlake M, Charitos E I, Erber K, et al. Preoperative plasma growth-differentiation factor-15 for prediction of acute kidney injury in patients undergoing cardiac surgery[J]. Crit Care, 2016, 20(1):317
[25] Bidadkosh A, Lambooy S P, Heerspink H J, et al. Predictive properties of biomarkers GDF-15, NTproBNP, and hs-TnT for morbidity and mortality in patients with type 2 diabetes with nephropathy[J].Diabetes Care, 2017, 40(6):784
[26] Mazagova M, Buikema H, Landheer S W, et al. Growth differentiation factor 15 impairs aortic contractile and relaxing function through altered caveolar signaling of the endothelium[J]. Am J Physiol Heart Circ Physiol, 2013, 304(5):H709
[27] Li H, Gao F, Xue Y, et al. Value of plasma growth differentiation factor-15 in diagnosis and evaluation of type 2 diabetic nephropathy [J]. Nan Fang Yi Ke Da Xue Xue Bao, 2014, 34(3):387
[28] Frimodt-M?覬ller M,von Scholten B J,Reinhard H, et al.Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes-an observational follow-up study[J]. PLoS One, 2018, 13(4):e0196634
[29] Shin M Y, Kim J M, Kang Y E, et al. Association between growth differentiation factor 15(GDF15)and cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus[J]. J Korean Med Sci,2016, 31(9):1413
[30] Ho J E, Hwang S J, Wollert K C, et al. Biomarkers of cardiovascular stress and incident chronic kidney disease[J]. Clin Chem, 2013, 59(11):1613
[31] Lajer M, Jorsal A,Tarnow L, et al.Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy[J]. Diabetes Care, 2010, 33(7):1567
[32] Resl M, Clodi M, Vila G, et al. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes[J]. Heart, 2016,102(24):1963
[33] HamonS M, Griffin T P, Islam M N, et al. Defining reference intervals for a serum growth differentiation factor-15(GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD)[J]. Clin Chem Lab Med, 2019,57(4):510
[34] Hellemons M E, Mazagova M, Gansevoort R T, et al. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes[J]. Diabetes Care, 2012，35(11):2340
[35] Ju W, Nair V, Smith S, et al. Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker[J]. Sci Transl Med, 2015, 7(316):316 ra193
[36] Rohatgi A, Patel P, Das S R, et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas heart study[J]. Clin Chem, 2012, 58(1):172
[37] Nair V, Robinson-Cohen C, Smith M R, et al. Growth differentiation factor-15 and risk of CKD progression[J]. J Am Soc Nephrol, 2017, 28(7):2233
[38] Zimmers T A, Jin X,Hsiao E C, et al. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury[J]. Shock, 2005, 23(6):543
[39] Zimmers T A, Gutierrez J C, Koniaris L G. Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer[J]. J Cancer Res Clin Oncol, 2010,136(4):571
[40] Lee J W, Chou C L, Knepper M A. Deep sequencing in microdissected renal tubules identifies nephron Segment-specific transcriptomes[J].J Am Soc Nephrol, 2015, 26(11):2669
[41] Lukaszyk E, Lukaszyk M, Koc-Zorawska E A, et al. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients[J]. Int Urol Nephrol, 2016, 48(6):839
[42] Na K R, Kim Y H, Chung H K, et al. Growth differentiation factor 15 as a predictor of adverse renal outcomes in patients with immunoglobulin A nephropathy[J]. Intern Med J, 2017, 47(12):1393
[43] Ham Y R, Song C H,Bae H J, et al. Growth differentiation factor-15 as a predictor of idiopathic membranous nephropathy progression: a retrospective study[J]. Dis Markers, 2018, 2018:1463940
[44] Bonaterra G A,Zügel S,Thogersen J, et al. Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury[J]. J Am Heart Assoc, 2012, 1(6):e002550
[45] George M,Jena A,Srivatsan V, et al. GDF 15 - A novel biomarker in the offing for heart failure[J]. Curr Cardiol Rev, 2016, 12(1):37
[46] Martini S, Nair V,Keller B J, et al. Integrative biology identifies shared transcriptional networks in CKD[J]. J Am Soc Nephrol, 2014,25(11):2559
[47] Roshanravan B, Khatri M, Robinson-Cohen C A, et al. A prospective study of frailty in Nephrology-Referred patients with CKD[J]. Am J Kidney Dis, 2012, 60(6):912
[48] Mazagova M, Buikema H, Van B A, et al. Genetic deletion of growth differentiation factor 15 augments renal damage in both type 1 and type 2 models of diabetes[J]. Am J Physiol Renal Physiol, 2013, 305(9):F1249
[49] Kim Y I, Shin H W, Chun Y S, et al. CST3 and GDF15 ameliorate renal fibrosis by inhibiting fibroblast growth and activation[J].Biochem Biophys Res Commun, 2018, 500(2):288
[50] Chrysovergis K, Wang X, Kosak J, et al. NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism[J]. Int J Obes, 2014, 38(12):1555
[51] Roshanravan B, Robinson-Cohen C, Patel K V, et al. Association between physical performance and all-cause mortality in CKD[J]. J Am Soc Nephrol, 2013, 24(5):822

相似文献/References:

备注/Memo

备注/Memo:
基金项目 天津市卫生和计划生育委员会中医中西医结合科研课题（2017161）
作者简介 郭小云（1980-）， 女， 主治医师， 硕士 ，研究方向：肾脏病学； 通信作者：李荣，E-mail：406928562@qq.com。
更新日期/Last Update: 2020-06-13